论文部分内容阅读
一些随机的临床试验报道,应用重组α干扰素治疗慢性乙型肝炎可使HBeAg转阴率从来治疗的5％～10％增至30％～50％。当血清HBeAg转化为HBeAg抗体时常伴有HBV DNA阴转。虽然有少数报道提出干扰素治疗可使慢性乙型肝炎的肝脏炎症减轻,但并未证明抗病毒治疗可影响预后。本文旨在确定。干扰素治疗使HBeAg转阴后能否改善临床表现。
Some randomized clinical trials have reported that the treatment of chronic hepatitis B with recombinant interferon alpha increases the rate of HBeAg negative conversion from 5% to 10% of those previously treated to 30% to 50%. When serum HBeAg is converted to HBeAg antibodies often accompanied by HBV DNA negative. Although few reports suggest that interferon treatment may reduce liver inflammation in chronic hepatitis B, it has not been shown that antiviral therapy can affect prognosis. This article aims to determine. Interferon treatment can make HBeAg negative can improve clinical performance.